Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: Insights from the TNT trial

Journal of the American College of Cardiology

Volumn 65, Issue 15, 2015, Pages 1539-1548

  Bangalore, Sripal ^a   Breazna, Andrei ^b   Demicco, David A ^b   Wun, Chuan Chuan ^b   Messerli, Franz H ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

cardiovascular outcomes; LDL cholesterol; variability

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DEATH; DRUG DOSE COMPARISON; HAZARD RATIO; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME; ADULT; AGED; ANGINA, UNSTABLE; BLOOD; CONTROLLED STUDY; FOLLOW UP; HEART ARREST; HEART MUSCLE REVASCULARIZATION; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; STROKE;

ADULT; AGED; ANGINA, UNSTABLE; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FOLLOW-UP STUDIES; HEART ARREST; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PYRROLES; STROKE;

EID: 84927578814     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.02.017     Document Type: Article

References (19)

1. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
2. J.C. LaRosa, S.M. Grundy, and D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
3. C. Baigent, A. Keech, and P.M. Kearney Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
4. Cholesterol Treatment Trialists Collaborators B. Mihaylova, and J. Emberson The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
5. F. Taylor, M.D. Huffman, and A.F. Macedo Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 CD004816
6. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
7. N.J. Stone, J. Robinson, and A.H. Lichtenstein 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
8. European Association for Cardiovascular Rehabilitation Z. Reiner ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
9. L. Yinon, Y. Chen, and F. Parvez A prospective study of variability in systolic blood pressure and mortality in a rural Bangladeshi population cohort Prev Med 57 2013 807 812
10. P.M. Rothwell, S.C. Howard, and E. Dolan Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension Lancet 375 2010 895 905
11. K. Kario, and T.G. Pickering Blood pressure variability in elderly patients Lancet 355 2000 1645 1646
12. R.P. Giugliano, N.R. Desai, and P. Kohli Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017
13. D.D. Waters, J.R. Guyton, and D.M. Herrington Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 93 2004 154 158
14. D.M. Mann, N.L. Glazer, and M. Winter A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol Am J Cardiol 111 2013 1437 1442
15. C. Meek, A.S. Wierzbicki, and C. Jewkes Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study Curr Med Res Opin 28 2012 371 378
16. M.S. Matalka, M.C. Ravnan, and P.C. Deedwania Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS) Am Heart J 144 2002 674 677
17. S.P. Kennedy, G.P. Barnas, and M.J. Schmidt Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance J Clin Lipidol 5 2011 308 315
18. J.M. Backes, C.V. Venero, and C.A. Gibson Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance Ann Pharmacother 42 2008 341 346
19. G.B. Mancini, A.Y. Tashakkor, and S. Baker Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update Can J Cardiol 29 2013 1553 1568